Overview

A Pharmacokinetic Study of CKD-501 in Patients With Impaired Hepatic Function

Status:
Completed

Trial end date:
2016-02-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate pharmacokinetics of CKD-501 in patients with impaired hepatic function compared with normal hepatic function.

Phase:

Phase 1

Details

Lead Sponsor:

Chong Kun Dang Pharmaceutical